Second cancers after adjuvant tamoxifen therapy for breast cancer.
Curtis
R E
RE
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Boice
J D
JD
Shriner
D A
DA
Hankey
B F
BF
Fraumeni
J F
JF
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D004965:Estrogen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000453:epidemiology; D016017:Odds Ratio; D012306:Risk; D018426:SEER Program; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D013629:Tamoxifen